Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30692102 | 0.78 | KDM4E (0.37) | TSHRALDH1A1USP2GAAPKM | |
| SCHEMBL12808355 | 0.77 | ALDH1A1 (0.34) | TSHRALDH1A1USP2GAAPKM | |
| SCHEMBL560581 | 0.75 | TSHR (0.39) | TSHRALDH1A1USP2GAAPKM | |
| SCHEMBL11415140 | 0.75 | TSHR (0.39) | TSHRALDH1A1USP2GAAPKM | |
| SCHEMBL2938448 | 0.72 | CYP3A4 (0.36) | TSHRALDH1A1GAATP53CYP3A4 | |
| SCHEMBL28877103 | 0.72 | TSHR (0.41) | TSHRALDH1A1USP2GAAPKM | |
| SCHEMBL10341214 | 0.72 | ALDH1A1 (0.36) | ALDH1A1USP2GAAPKMHPGD | |
| SCHEMBL10341247 | 0.72 | TSHR (0.31) | TSHRALDH1A1USP2GAAPKM | |
| SCHEMBL31261129 | 0.71 | ALDH1A1 (0.39) | TSHRALDH1A1GAATP53CYP3A4 | |
| SCHEMBL118738 | 0.71 | ALDH1A1 (0.39) | TSHRALDH1A1GAATP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-10-03 | — | — | US | disclosed |
| US-10138220-B1 | Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2018-11-27 | — | — | US | disclosed |
| US-9975875-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170362200-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | Theravance Respiratory Compa, LLC | 2017-12-21 | — | — | US | disclosed |
| US-9771350-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170226082-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2017-08-10 | — | — | US | disclosed |
| EP-2414418-B1 | COMPOSITION CURABLE IN TWO STAGES COMPRISING A SURFACE DEACTIVATED POLYISOCYANATE | SIKA TECH AG (CH) | 2017-08-09 | — | — | EP | disclosed |
| US-9011630-B2 | Hot curing or heat-activated composition containing a surface-deactivated polyisocyanate | SIKA TECHNOLOGIES AG (CH) | 2015-04-21 | — | — | US | disclosed |
| US-8759455-B2 | Two-stage curable composition containing a surface-deactivated polyisocyanate | SIKA TECHNOLOGY AG (CH) | 2014-06-24 | — | — | US | disclosed |
| EP-2236535-A1 | Humidity curing polyurethane composition being accelerated by influence of heat | Sika Technology AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| EP-2225298-A1 | CURABLE COMPOSITIONS HAVING LESS VOLATILIZATION | Sika Technology AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2010063741-A1 | ALDIMINE AND COMPOSITION CONTAINING ALDIMINE | SIKA TECHNOLOGY AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| EP-2194082-A1 | Aldimine and composition comprising aldimine | Sika Technology AG (CH) | 2010-06-09 | — | — | EP | disclosed |
| EP-2189484-A1 | Polyurethane composition comprising organomethoxysilane having anisostropic material properties | Sika Technology AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| EP-2189485-A1 | Polyurethane composition comprising alpha-silane having anisostropic material properties | Sika Technology AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| WO-2010049516-A1 | POLYURETHANE COMPOSITION THAT CONTAINS ORGANOMETHOXYSILANE AND HAS ANISOTROPIC MATERIAL PROPERTIES | SIKA TECHNOLOGY AG (CH) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010049518-A1 | POLYURETHANE COMPOSITION THAT CONTAINS ALPHA-SILANE AND HAS ANISOTROPIC MATERIAL PROPERTIES | SIKA TECHNOLOGY AG (CH) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009080738-A1 | CURABLE COMPOSITIONS HAVING LESS VOLATILIZATION | SIKA TECHNOLOGY AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| EP-2072550-A1 | Hardening compounds with reduced gas emission | Sika Technology AG (CH) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | TSHR 90/4885ALDH1A1 1263/4885USP2 3493/4885 |
| US-10138220-B1 | Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | TSHR 105/4885ALDH1A1 1710/4885USP2 3579/4885 |
| US-20170226082-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2A | TSHR 133/4885ALDH1A1 857/4885USP2 2629/4885 |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | TSHR 90/4885ALDH1A1 1263/4885USP2 3493/4885 |
| US-20170362200-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2A | TSHR 133/4885ALDH1A1 857/4885USP2 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.